Restricted accessResearch articleFirst published online 2013-09
Predictive Factors for Agitation Severity of Hyperactive Delirium in Terminally Ill Cancer Patients in a General Hospital Using Ordered Logistic Regression Analysis
Despite the fact that many cancer patients worldwide die in general hospitals, there are few reports of the analysis of delirium in terminally ill cancer patients in this setting.
Purpose:
This study aimed to identify predictive factors for agitation severity of hyperactive delirium in terminally ill cancer patients in a general hospital.
Methods:
Participants were 182 consecutively admitted terminally ill cancer patients who died in a Japanese general hospital between April 2009 and March 2011. Variables present one week before death were extracted from the clinical records for regression analysis of factors potentially related to agitation severity of delirium. The prevalence and agitation severity of delirium were evaluated retrospectively. Multivariate ordered logistic regression analysis was performed to identify predictive factors.
Results:
Male sex [odds ratio (OR)=2.125, 95% confidence interval (CI)=1.111–4.067; P=0.0227]; total bilirubin (T-bil) [OR=1.557, CI=1.082–2.239; P=0.017]; antibiotics [OR=0.450, CI=0.219–0.925; P=0.0298]; nonsteroidal antiinflammatory drugs (NSAIDs) [OR=2.608, CI=1.374–4.950; P=0.0034]; and hematological malignancy [OR=3.903, CI=1.363–11.179; P=0.0112] were found to be statistically significant predictors for agitation severity of hyperactive delirium.
Conclusions:
Our study indicates that male sex, T-bil, antibiotic therapy, NSAID therapy, and hematological malignancy are significant predictors for agitation severity of hyperactive delirium in terminally ill cancer patients in a general hospital setting.
Get full access to this article
View all access options for this article.
References
1.
BrueraE, MillerL, McCallionJ, MacmillanK, KreftingL, HansonJ. Cognitive failure in patients with terminal cancer: A prospective study. J Pain Symptom Manage, 1992; 7:192–195.
2.
PereiraJ, HansonJ, BrueraE. The frequency and clinical course of cognitive impairment in patients with terminal cancer. Cancer, 1997; 79:835–842.
3.
LawlorPG, GagnonB, ManciniIL, PereiraJL, HansonJ, Suarez-AlmazorME, BrueraED. Occurrence, causes, and outcome of delirium in patients with advanced cancer: A prospective study. Arch Intern Med, 2000; 160:786–794.
4.
MoritaT, TeiY, TsunodaJ, InoueS, ChiharaS. Underlying pathologies and their associations with clinical features in terminal delirium of cancer patients. J Pain Symptom Manage, 2001; 22:997–1006.
5.
GagnonP, AllardP, GagnonB, MéretteC, TardifF. Delirium prevention in terminal cancer: Assessment of a multicomponent intervention. Psychooncology, 2012; 21:187–194.
6.
CaraceniA, SimonettiF. Palliating delirium in patients with cancer. Lancet Oncol, 2009; 10:164–172.
7.
WhiteC, McCannMA, JacksonN. First do no harm.. Terminal restlessness or drug-induced delirium. J Palliat Med, 2007; 10:345–351.
8.
AlagiakrishnanK, WiensCA. An approach to drug induced delirium in the elderly. Postgrad Med J, 2004; 80:388–393.
9.
BreitbartW, GibsonC, TremblayA. The delirium experience: Delirium recall and delirium-related distress in hospitalized patients with cancer, their spouses/caregivers, and their nurses. Psychosomatics, 2002; 43:183–194.
10.
MoritaT, HiraiK, SakaguchiY, TsunetoS, ShimaY. Family-perceived distress from delirium-related symptoms of terminally ill cancer patients. Psychosomatics, 2004; 45:107–113.
BreitbartW, ChochinovHM, PassikSD. Psychiatric aspects of palliative care. DoyleD, HanksGW, MacDonaldN. Oxford Textbook of Palliative Medicine, 2nd. New York: Oxford University Press, 1998; 216–247.
13.
MoritaT, TeiY, InoueS. Impaired communication capacity and agitated delirium in the final week of terminally ill cancer patients: Prevalence and identification of research focus. J Pain Symptom Manage, 2003; 26:827–834.
14.
FriedTR, van DoornC, O'LearyJR, TinettiME, DrickamerMA. Older persons' preferences for site of terminal care. Ann Intern Med, 1999; 131:109–112.
15.
CohenJ, HouttekierD, Onwuteaka-PhilipsenB, MiccinesiG, Addington-HallJ, KaasaS, BilsenJ, DeliensL. Which patients with cancer die at home? A study of six European countries using death certificate data. J Clin Oncol, 2010; 28:2267–2273.
16.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4thText revision. DSM IV–TR. Washington, DC: American Psychiatric Press, 2000.
17.
InouyeSK, Leo-SummersL, ZhangY, BogardusSTJr, LeslieDL, AgostiniJV. A chart-based method for identification of delirium: Validation compared with interviewer ratings using the confusion assessment method. J Am Geriatr Soc, 2005; 53:312–318.
18.
BreitbartW, RosenfeldB, RothA, SmithMJ, CohenK, PassikS. The Memorial Delirium Assessment Scale. J Pain Symptom Manage, 1997; 13:128–137.
19.
NagaseM, OkamotoY, TsunetoS, TanimukaiH, MatsudaY, OkishiroN, OonoY, TsuganeM, TakagiT, UejimaE. A retrospective chart review of terminal patients with cancer with agitation and their risk factors. J Palliat Med, 2012; 15:1185–1190.
20.
MoritaT, TsunodaJ, InoueS, ChiharaS, OkaK. Communication Capacity Scale and Agitation Distress Scale to measure the severity of delirium in terminally ill cancer patients: A validation study. Palliat Med, 2001; 15:197–206.
21.
MoritaT, ChinoneY, IkenagaM, MiyoshiM, NakahoT, NishitatenoK, SakonjiM, ShimaY, SuenagaK, TakigawaC, KoharaH, TaniK, KawamuraY, MatsubaraT, WatanabeA, YagiY, SasakiT, HiguchiA, KimuraH, AboH, OzawaT, KizawaY, UchitomiY. Japan Pain, Palliative Medicine, Rehabilitation, Psycho-Oncology Study Group: Efficacy and safety of palliative sedation therapy: A multicenter, prospective, observational study conducted on specialized palliative care units in Japan. J Pain Symptom Manage, 2005; 30:320–328.
22.
LawlorPG, NekolaichukC, GagnonB, ManciniIL, PereiraJL, BrueraED. Clinical utility, factor analysis, and further validation of the memorial delirium assessment scale in patients with advanced cancer: Assessing delirium in advanced cancer. Cancer, 2000; 88:2859–2867.
23.
HanksGCW, ChernyN. Opioid analgesic therapy. DoyleD, HanksGCW, MacDonaldN. Oxford Textbook of Palliative Medicine, 2nd. New York: Oxford Medical Publications, 1998; 331–355.
24.
DurandF, VallaD. Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. J Hepatol, 2005; 42:S100–S107.
25.
DuboisMJ, BergeronN, DumontM, DialS, SkrobikY. Delirium in an intensive care unit: A study of risk factors. Intensive Care Med, 2001; 27:1297–1304.
26.
SchorJD, LevkoffSE, LipsitzLA, ReillyCH, ClearyPD, RoweJW, EvansDA. Risk factors for delirium in hospitalized elderly. JAMA, 1992; 267:827–831.
HoppmannRA, PedenJG, OberSK. Central nervous system side effects of nonsteroidal anti-inflammatory drugs: Aseptic meningitis, psychosis, and cognitive dysfunction. Arch Intern Med, 1991; 151:1309–1313.
29.
CunninghamC, SkellyDT. Non-steroidal anti-inflammatory drugs and cognitive function: Are prostaglandins at the heart of cognitive impairment in dementia and delirium?J Neuroimmune Pharmacol, 2012; 7:60–73.
30.
DavisMP, WalshD, LagmanR, LeGrandSB. Controversies in pharmacotherapy of pain management. Lancet Oncol, 2005; 6:696–704.
31.
FadulNA, El OstaB, DalalS, PoulterVA, BrueraE. Comparison of symptom burden among patients referred to palliative care with hematologic malignancies versus those with solid tumors. J Palliat Med, 2008; 11:422–427.
32.
ZeeviN, PachterJ, McCulloughLD, WolfsonL, KuchelGA. The blood-brain barrier: Geriatric relevance of a critical brain-body interface. Am Geriatr Soc, 2010; 58:1749–1757.
